ONCOLYTICS BIOTECH INC 8-K

What Happened
On May 4, 2026, Oncolytics Biotech Inc. (ONCY) filed a Form 8‑K (Item 8.01) to report that it issued a press release with updates from the REO‑022 study in metastatic colorectal cancer (mCRC). The press release is included as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 4, 2026; Form 8‑K Item 8.01 (Other Events).
• Study referenced: REO‑022 (indication: metastatic colorectal cancer).
• Exhibit attached: 99.1 — press release dated May 4, 2026; Exhibit 104 is the Interactive XBRL cover file.
• Form signed by CFO Kirk Look on behalf of the company.

Why It Matters
Clinical trial updates can be material for a biotech company because they may influence the clinical and regulatory outlook, partnership opportunities, and investor sentiment. This 8‑K notifies investors that new information about the REO‑022 mCRC study has been released; investors should read the attached press release (Exhibit 99.1) and company communications for the specific clinical data or milestones disclosed. The filing does not itself present financial results or executive changes.